Celcuity Inc. (CELC): Price and Financial Metrics


Celcuity Inc. (CELC): $8.06

-0.19 (-2.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CELC Stock Price Chart Interactive Chart >

Price chart for CELC

CELC Price/Volume Stats

Current price $8.06 52-week high $14.78
Prev. close $8.25 52-week low $4.81
Day low $7.79 Volume 7,500
Day high $8.35 Avg. volume 56,920
50-day MA $9.79 Dividend yield N/A
200-day MA $8.82 Market Cap 124.61M

Celcuity Inc. (CELC) Company Bio


Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.


CELC Latest News Stream


Event/Time News Detail
Loading, please wait...

CELC Latest Social Stream


Loading social stream, please wait...

View Full CELC Social Stream

Latest CELC News From Around the Web

Below are the latest news stories about CELCUITY INC that investors may wish to consider to help them evaluate CELC as an investment opportunity.

Celcuity to Present Additional Data for Gedatolisib at the 2022 San Antonio Breast Cancer Symposium

/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for cancer treatment, today announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) is now available on the SABCS website.

Yahoo | November 22, 2022

Needham Sticks to Its Buy Rating for Celcuity (CELC)

In a report released today, Gil Blum from Needham reiterated a Buy rating on Celcuity (CELC - Research Report), with a price target of $25.00. The company's shares closed yesterday at $10.00.Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Geron, and Rocket Pharmaceuticals. According to TipRanks, Blum has an average return of -22.4% and a 29.02% success rate on recommended stocks. Celcuity has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.See Insiders’ Hot Stocks on TipRanks >> Based on Celcuity's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.

Carrie Williams on TipRanks | November 11, 2022

Celcuity to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that Brian Sullivan, Chairman, Chief Executive Officer, and Co-founder of Celcuity, will participate in one-on-one and small group meetings at the 13th Annual Craig-Hallum Alpha Select Conference in New York on Thursday, November 17, 2022.

Yahoo | November 10, 2022

Celcuity Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced financial results for the third quarter ended September 30, 2022 and other recent business developments.

Yahoo | November 10, 2022

Celcuity Inc. Schedules Release of Third Quarter 2022 Financial Results and Webcast/Conference Call

/ Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced that it will release its financial results for the third quarter 2022 after the stock market close on Thursday, November 10, 2022. Management will host a webcast/teleconference the same day at 4:30 p.m.

Yahoo | November 3, 2022

Read More 'CELC' Stories Here

CELC Price Returns

1-mo -19.32%
3-mo -8.51%
6-mo 5.91%
1-year -39.58%
3-year -25.65%
5-year -55.20%
YTD -38.89%
2021 44.00%
2020 -13.91%
2019 -55.65%
2018 26.60%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7473 seconds.